- Home
- EIX vs EXAS Comparison
EIX vs EXAS Comparison
Compare EIX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIX | EXAS |
|---|---|---|
| Founded | 1886 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 19.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EIX | EXAS |
|---|---|---|
| Price | $61.58 | $102.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 20 |
| Target Price | $64.55 | ★ $80.25 |
| AVG Volume (30 Days) | ★ 3.1M | 2.5M |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | ★ 5.70% | N/A |
| EPS Growth | ★ 123.49 | N/A |
| EPS | ★ 7.64 | N/A |
| Revenue | ★ $18,088,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | $7.07 | $19.40 |
| Revenue Next Year | $2.47 | $13.51 |
| P/E Ratio | $8.07 | ★ N/A |
| Revenue Growth | 4.43 | ★ 14.47 |
| 52 Week Low | $47.73 | $38.81 |
| 52 Week High | $63.97 | $102.66 |
Technical Indicators
Market Signals| Indicator | EIX | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 84.58 |
| Support Level | $59.68 | $101.51 |
| Resistance Level | $62.16 | $102.56 |
| Average True Range (ATR) | 1.22 | 0.34 |
| MACD | 0.07 | -0.69 |
| Stochastic Oscillator | 85.30 | 89.05 |
Price Performance
Historical ComparisonAbout EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.